Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus MPI KRYPTON 81M GENERATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus MPI KRYPTON 81M GENERATOR.
MPI DMSA KIDNEY REAGENT vs MPI KRYPTON 81M GENERATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical